Euphrates Vascular

Executive Summary

Euphrates Vascular is a private medical device company based in San Diego, founded in 2018, that leverages nanotechnology to optimize blood flow and treat distal vessel occlusions across three major vascular indications: Acute Ischemic Stroke (AIS), Peripheral Artery Disease (PAD), and ST-Elevated Myocardial Infarction (STEMI). The company's proprietary platform aims to improve outcomes in these high-acuity settings by enabling precise, minimally invasive interventions. With a focus on underserved distal vessel territories, Euphrates Vascular addresses a critical gap in current endovascular therapy, where small-caliber, tortuous vessels often limit the efficacy of existing devices. To date, Euphrates Vascular has advanced its technology through preclinical and early clinical studies, positioning itself for pivotal trial initiation. The company's management team combines deep expertise in interventional cardiology, neuroradiology, and nanotechnology. While still operating under limited public disclosure, the company's approach has attracted interest from strategic partners and investors seeking next-generation solutions for high-volume vascular procedures. With an estimated multiple near-term catalysts, Euphrates Vascular represents a promising opportunity in the cardiovascular and neurovascular medical device space, contingent on successful trial execution and regulatory milestones.

Upcoming Catalysts (preview)

• Q3 2026Pivotal Clinical Trial Initiation for AIS70% success
• Q1 2027FDA 510(k) Submission for PAD Indication60% success
• TBDStrategic Partnership with Major Medical Device Company50% success